APA (7th ed.) Citation

Subbiah, V., Hu, M. I., Mansfield, A. S., Taylor, M. H., Schuler, M., Zhu, V. W., . . . Trask, P. (2024). Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study. Thyroid, 34(1), 26. https://doi.org/10.1089/thy.2023.0363

Chicago Style (17th ed.) Citation

Subbiah, Vivek, et al. "Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study." Thyroid 34, no. 1 (2024): 26. https://doi.org/10.1089/thy.2023.0363.

MLA (9th ed.) Citation

Subbiah, Vivek, et al. "Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study." Thyroid, vol. 34, no. 1, 2024, p. 26, https://doi.org/10.1089/thy.2023.0363.